Search Grants — Free, No Account Required

Orchestra of New Spain (dba)

To support the Summer Strings Camp for at-risk youth in Dallas ISD.

Plano Symphony Orchestra

To support Healing Notes, a series of interactive concerts for incarcerated youth, in partnership with the John R. Roach Juvenile Detention Center of Collin County.

Chinati Foundation/La Fundacion Chinati

To support the annual Chinati Weekend, which will feature exhibitions and a variety of activities designed to attract Marfa residents as well as state, national, and international visitors.

Chamberlain Ballet Company

To support the Releve After-School Dance Program, consisting of after-school dance classes for economically disadvantaged students in Collin, Dallas, and Denton counties.

Lubbock Symphony Orchestra

To support the Listen Live and Teen Education Concerts, which provide a free performance and complementary guidebook to K-12th grade students from the Lubbock area.

Mercury Houston

To support educational, in-school chamber orchestra performances for K-12th grade students at Title I schools in the Houston Independent School District.

Dallas Theater Center

To support Project Discovery, an award-winning after-school program which provides free in-depth theater experiences for at-risk teens from north Texas high schools.

Chinatown-International District Exhibit Committee

The Chinatown-International District Exhibit Committee's COVID-19 Exhibit will educate the public about the effects of COVID-19 on Asian Pacific Islander Americans in the Chinatown-International District through a free digital exhibit of art, personal stories, and artifacts. This project is a partnership with the Wing Luke Museum located at 719 S King Street. This project will be completed by December 31,2021.

NIA - National Institute on Aging

ABSTRACT The ASPIRE: Alzheimer’s Summer Program Inspiring Research Engagement (T35 mechanism) at the Krieger Klein Alzheimer’s Research Center at Rutgers is designed to inspire and prepare medical students to pursue careers in bridging ADRD research and clinical care. This summer program offers 10-week, full-time immersive research experiences to 10 medical students per summer, under the mentorship of 10 accomplished scientists. These mentors, with active NIH funding portfolios and proven mentoring success, ensure trainees receive high-quality guidance and sufficient resources. The program will establish internal and external advisory committees to ensure optimal learning goals for the students in ADRD research. Participants will engage in research projects spanning epidemiological observational studies, lifestyle and medication clinical trials, data analyses of "big data" (including “omics” and medical chart data), digital health innovations, and basic science (animal, cellular/molecular, neural stem cell and human postmortem tissue systems studies). This hands-on experience will be complemented by exposure to data science and biostatistics through dedicated meetings with a program biostatistician, equipping students with basic yet practical analytical skills essential for addressing complex challenges in ADRD research. The program emphasizes the responsible conduct of research, including practices that enhance rigor and transparency in human subjects and animals research. Students will also participate in the ADRD Translational Work in Progress series, engaging in open discussions and critiques of scientific materials such as grant aims and hypothesis development. This interactive environment motivates critical thinking, collaboration, and scientific communication skills. Internal and External Advisory Committees, each including world-class researchers in neurodegeneration and ADRD, will meet annually to monitor program progress and provide recommendations for improvement. This oversight ensures alignment with the highest standards of mentorship while maximizing each student’s research experience. The program culminates in a symposium where trainees present their research findings, further refining their scientific communication skills. By exposing medical students to ADRD research early in their clinician careers, the program addresses the critical need for developing future physician-scientists dedicated to ADRD, a condition that disproportionately affects older adults, the fastest-growing segment of the U.S. population. The program aims to cultivate future leaders who will advance innovative research, ultimately promoting state-of-the-art, compassionate care for ADRD patients and improving health outcomes for the rapidly growing geriatric population.

NHLBI - National Heart Lung and Blood Institute

PROJECT SUMMARY/ABSTRACT Cardiovascular disease is the leading cause of death in the United States, and heart failure (HF) rates in particular are escalating at alarming rates in the general population, with approximately one in four adults in the United States anticipated to develop HF in their lifetime. Today, HF affects an estimated 6.7 million American adults and is associated with a high risk for premature death, hospitalizations, and poorer quality of life. For the aging cohort of people with HIV (PWH)—who are living longer lives thanks to the advent of antiretroviral therapy (ART)—there is a well-established higher risk of atherosclerotic cardiovascular disease (ASCVD) driven by a higher prevalence of traditional and HIV-specific risk factors. Unfortunately, there is very limited research for HF in PWH, largely due to the scarcity of large longitudinal cohorts and the difficulties involved in reliably identifying HF cases. In one of the few studies on the topic, a large multicenter analysis from Kaiser Permanente (KP) demonstrated a 73% higher risk of developing HF in PWH compared with demographically matched people without HIV (PWoH). Thus, there is now an urgent need for a clear understanding of the underlying drivers of risk in PWH. To address critical uncertainties in the field—and ultimately to inform strategies for HF risk prediction and prevention among aging PWH—we propose a cohort study in three integrated health systems with an overarching goal to improve our understanding of contributors to the elevated HF risk in PWH. Our specific aims include: (1) comparing the impact of traditional and HIV-specific risk factors on the risk of incident HF among PWH and PWoH; (2) evaluating and refining the recently introduced American Heart Association Predicting Risk of CVD EVENTs in HF (PREVENT-HF) equations specifically for PWH; and (3) evaluating the impact of medications—including statins and ART classes—on the risk of HF among PWH. We plan to evaluate these aims using advanced biostatistical methods for the development, calibration, and validation of HF prediction models and applying causal inference techniques to evaluate medication effectiveness using observational data. The study will be conducted in three US healthcare delivery systems—KP Northern and Southern California and Mass General Brigham—where we anticipate a cohort of over 50,000 PWH and 10:1 matched PWoH from 2008–2025, with a highly sensitive approach for ascertainment of HF cases using a validated natural language processing algorithm. Study innovations include: (1) exceptional cohort of PWH and matched PWoH with comprehensive electronic health record data and validated HF outcomes; (2) first-of-its-kind analysis of the PREVENT-HF equations in PWH; and (3) use of advanced analytics to evaluate medication effectiveness for preventing HF. This study has great potential to generate critical evidence to guide HIV-specific HF risk prediction and prevention strategies, ultimately reducing HF incidence in PWH.

NIAID - National Institute of Allergy and Infectious Diseases

Summary Despite significant progress in combating HIV, an effective vaccine is still elusive. On the other hand, passive immunization with broadly neutralizing antibodies (bnAbs) used in therapy or prophylaxis show promise in reducing in complementing current antiretroviral therapies (ART) and reducing the rate of new infections. However, more work is needed in understanding viral resistance to bnAbs and bnAb escape, as well as the effect of bnAbs on immune responses. Our overarching goal is to investigate the impact of the presence of the monoclonal bnAb VRC01 at HIV acquisition on viral diversity and host antibody responses. We hypothesize that if VRC01 prophylaxis has immunomodulatory effects on breakthrough infections, we would observe lower viral diversity at rebound after treatment interruption and/or earlier emergence of neutralizing autologous antibody responses in VRC01 recipients compared to placebo. We will address these questions by leveraging longitudinal data (anticipated and already acquired) from the Antibody Mediated Protection (AMP) trial HVTN 704 and the follow-up Analytic Treatment Interruption (ATI) trial HVTN 804, which enrolled study participants from Lima, Peru. These trials were designed to assess immunologic and virologic responses during ART interruption in AMP study participants who acquired HIV while receiving either placebo or VRC01 prophylaxis and started ART shortly after infection. This proposal addresses analyses not currently funded by the HIV Vaccine Trial Network (HVTN) that are nonetheless critical to understand the immunomodulatory function of passively administered bnAbs in both therapy and prophylaxis. Understanding the impact of VRC01 on autologous immune responses and intra-host viral evolution will inform ongoing and upcoming clinical trials testing bnAb therapy and prevention and help devise strategies to minimize bnAb escape while harnessing the potential benefit of immune enhancement. Analysis of high-throughput deep sequencing data will allow detection of rebound lineages at higher resolution compared to previous studies, especially transitory low-frequency lineages that may have otherwise gone undetected and could offer important clues on the selective pressures acting on the virus.

NIAID - National Institute of Allergy and Infectious Diseases

Summary/Abstract: The advent of antiretroviral therapy (ART) has transformed HIV infection from a fatal disease into a manageable chronic condition. However, people living with HIV continue to experience comorbidities linked to persistent immune activation and inflammation. Unfortunately, there is not a functional vaccine for HIV, and recent efforts to achieve protection through passive immunization with broadly neutralizing anti-HIV IgG antibodies have not been successful. One promising avenue is anti-HIV IgA immunotherapy. Our recent published findings demonstrate that intrarectally applied anti-HIV IgA has an effect on the dissemination of HIV to lymph nodes following intra-rectal challenge. Elucidating the role of biochemical properties, such as glycosylation, on regulating the transport and effector functions of anti-HIV IgA remains poorly understood and requires further investigation. Our previous studies demonstrate that the glycosylation pattern of an anti-HIV IgG monoclonal antibody can influence its ability to disseminate across the blood brain barrier. In addition, we found that glycoengineered IgA isolated from colostrum exhibit altered transport properties. Taken together, these findings support our hypothesis that the glycosylation of IgA influences its cellular transport and can be strategically modified to enhance its transcytosis and function. In aim 1 we will characterize the glycosylation patterns of bulk IgA isolated from people living with HIV and compare them to non-HIV controls. We will then assess how these glycosylation profiles influence endothelial transport and how these changes correlate with viral load. In aim 2 we will clone anti-HIV monomeric IgA and express in 293 freestyle cells that have glycosl- transferases knocked down in order to create glycoengineered IgA. We will define the optimal glycosylation patterns that maximize endothelial transcytosis and antiviral effector functions. We have assembled a team of investigators uniquely equipped to carry out the aims of this grant.

NIAID - National Institute of Allergy and Infectious Diseases

Abstract Significance: HIV persists in long-lived CD4⁺ T cell reservoirs despite suppressive ART, as integrated proviruses remain poised for reactivation. Chromatin remodeling is a central barrier to durable silencing, yet most studies have focused on SWI/SNF family members. The roles of non- SWI/SNF remodelers remain poorly defined, limiting our ability to rationally design host-directed “block-and-lock” cure strategies. Our unbiased shRNA screen of all 16 human remodeler ATPases identified EP400, CHD1, and CHD9 as repressors and INO80A, SMARCA5, and CHD2 as activators, establishing chromatin remodeling as a key determinant of HIV latency. Innovation: Our prior studies revealed that the p400 complex regulates HIV transcription through dual mechanisms: directly, by engaging Tat via the DMAP1 subunit to block Tat-TAR RNA interactions and restrict p-TEFb recruitment; and indirectly, by altering host transcriptional programs that control T cell activation states. Building on this mechanistic precedent and methodological platform, we now focus on INO80A, SMARCA5, CHD1, and CHD2, remodelers from distinct ATPase families that govern Tat-independent checkpoints at initiation, pause release, and elongation. Methodologically, we will apply TurboID-ChAP-MS (locus-specific proteomics), BEM-seq (single-nucleosome mapping), and degron-mediated acute depletion with ATPase-dead rescue to interrogate remodeler function with unprecedented resolution. Approach: Aim 1 will define the ATPase requirement and transcriptional checkpoints regulated by INO80A, SMARCA5, CHD1, and CHD2 using degron/CRISPR perturbations, ChIP-seq, nascent RNA profiling, and nucleosome mapping. Aim 2 will characterize remodeler-specific complexes and Tat dependence at the HIV promoter via TurboID proximity labeling integrated with chromatin affinity purification-mass spectrometry. Aim 3 will test combinatorial perturbations in Jurkat and primary CD4⁺ T cell latency models, including ART-suppressed donor cells, to identify synergistic “block-and-lock” strategies that enforce durable proviral silencing. Impact: By defining remodeler-specific mechanisms at discrete transcriptional checkpoints and leveraging their enzymatic, druggable activities, this work will establish chromatin remodeling as a therapeutic axis for durable HIV suppression and functional cure.

City of Austin Cultural Arts Division

Grants supporting arts organizations, individual artists, and cultural programming in Austin. Includes project grants, organizational support, and cultural heritage preservation.

U.S. Mission to Austria

This is an Annual Program Statement, outlining our funding priorities, the strategic themes we focus on, and the procedures for submitting requests for funding. Purpose of Small Grants: The Austrian-American Partnership Fund (AAPF) is organized to fund projects advancing collaboration and dialogue and expand cooperation between Austria and the United States. AAPF accepts applications for funding for innovative projects that seek to bring American perspectives to Austria or connect Americans and Austrians in the following priority areas: Promote understanding of U.S. global foreign policy and economic priorities and interests among Austrian publics, particularly young people, and support U.S.-Austrian initiatives that advance these priorities. Contribute to strengthening U.S.-Austria efforts to combat shared transnational threats, such as terrorism, illegal migration, antisemitism, or drug trafficking. Enhance understanding of the United States and U.S.-Austrian shared history and celebrate American arts, film, sports, and music, particularly among youth, including in connection with America s 250th anniversary in 2026. Highlight American technological and scientific innovation and economic dynamism and create opportunities for U.S.-Austria collaboration in these fields. Proposals will be considered on a rolling basis and subject to the availability of Public Diplomacy funds for Fiscal Year 2026. The selection process can take up to two - three months. ELIGIBILITY The Public Diplomacy Section encourages applications from Austria, European or, U.S.-based organizations and individuals with proven experience of executing programs. Proposals that demonstrate the long-term sustainability of the proposed project will receive priority. The following organizations are eligible to apply: Not-for-profit organizations, including think tanks and civil society/non-governmental organizations Public and private educational institutions Individuals

U.S. Mission to Austria

This is an Annual Program Statement, outlining our funding priorities, the strategic themes we focus on, and the procedures for submitting requests for funding. Purpose of Small Grants: The Austrian-American Partnership Fund (AAPF) is organized to fund projects advancing collaboration and dialogue and expand cooperation between Austria and the United States. AAPF accepts applications for funding for innovative projects that seek to bring American perspectives to Austria or connect Americans and Austrians in the following priority areas: • Promote understanding of U.S. global foreign policy and economic priorities and interests among Austrian publics, particularly young people, and support U.S.-Austrian initiatives that advance these priorities. • Contribute to strengthening U.S.-Austria efforts to combat shared transnational threats, such as terrorism, illegal migration, antisemitism, or drug trafficking. • Enhance understanding of the United States and U.S.-Austrian shared history and celebrate American arts, film, sports, and music, particularly among youth, including in connection with America’s 250th anniversary in 2026. • Highlight American technological and scientific innovation and economic dynamism and create opportunities for U.S.-Austria collaboration in these fields. Proposals will be considered on a rolling basis and subject to the availability of Public Diplomacy funds for Fiscal Year 2026. The selection process can take up to two - three months. ELIGIBILITY The Public Diplomacy Section encourages applications from Austria, European or, U.S.-based organizations and individuals with proven experience of executing programs. Proposals that demonstrate the long-term sustainability of the proposed project will receive priority. The following organizations are eligible to apply: • Not-for-profit organizations, including think tanks and civil society/non-governmental organizations • Public and private educational institutions • Individuals

NIH

ABSTRACT Significance to VA: Knee osteoarthritis is a major health problem in Veterans and accounts for approximately one-half of all joint replacement surgeries in the VA system. Total knee arthroplasty is the current standard of care to treat advanced knee osteoarthritis and is effective in reducing pain. However, nearly 1 in 4 patients report not being satisfied with their surgery. While the reasons for this high number of unsatisfied patients is multifactorial, poor knee function is a major driver behind poor outcomes. Clinical research studies often characterize functional deficits by evaluating Arthrogenic Muscle Inhibition (AMI). But these evaluations typically require the patient to maximally contract their muscles, which often causes pain and leads to unreliable results. Additionally, specialized equipment and highly trained investigators are essential for reliable measurements. Innovation and Impact: This project addresses these challenges in quantifying AMI by developing, validating, and implementing a novel nerve stimulating platform called the Smart Nerve Stimulator to quantify Arthrogenic Muscle Inhibition (AMI) in Veterans before and after undergoing total knee arthroplasty surgery. This is an impactful innovation because it addresses an unmet clinical need by leveraging state-of-the-art electrode technology and a custom-developed user interface to establish the first-of-its-kind neuromechanical database in Veterans with knee pain. We expect that this will serve as a novel biomarker of knee health and support future VA research aimed at improving therapeutics for Veterans with knee osteoarthritis. Specific Aims: This device development Merit application has 3 aims. Aim 1 will optimize a fully automated nerve conduction testing tool using custom developed software and high-density stimulating and recording electrode arrays. Aim 2 will establish the first-of-its-kind Neuromechanical Database to Advance Veteran Health. Aim 3 will develop a novel AMI biomarker using machine learning. Methodology: This study uses an iterative design cycle in Aim 1 to optimize a working prototype that leverages our automated software interface and designs, fabricates, and deploys high-density stimulating and recording electrodes. Our Smart Nerve Stimulator will quantify AMI as the ratio H-reflex:M-max that represents the spinal and muscle excitability. Aim 2 uses a cross-sectional study design to evaluate arthrogenic muscle inhibition in 3 Veteran groups: 1) Veterans with knee osteoarthritis who are scheduled to undergo total knee arthroplasty surgery, 2) Veterans who are age/sex-matched but without any knee symptoms or pathology, and 3) Veterans who are 25-45 years of age and sex-matched without any knee symptoms or pathology. Aim 3 uses our innovative biomechanically informed latent neuromechanical dynamics learning architecture to automatically differentiate between Veterans with knee osteoarthritis, total knee arthroplasty, and healthy controls. We will quantify arthrogenic muscle inhibition before and after total knee arthroplasty to evaluate the effects of surgery on neuromechanical function. We will also quantify arthrogenic muscle inhibition with young and age-matched Veterans without knee pain to establish test-retest reliability. Path to Translation/Implementation: Our Smart Nerve Stimulator has strong paths towards translation towards commercialization as well as implementation into knee osteoarthritis research conducted at the CReATE Motion Center at the CMCVAMC and Atlanta VAMC. Our team will work with the University of Pennsylvania and CMCVAMC to protect our intellectual property and evaluate a path towards commercialization.

NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases

PROJECT SUMMARY/ABSTRACT Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the US population and has been identified as a leading cause of type II diabetes, hepatocellular carcinoma, and is now the most prevalent disease leading to liver transplantation. A defining feature of MASLD is the accumulation of unique triglyceride-rich organelles called lipid droplets (LDs). Understanding the fundamental mechanisms that regulate the hepatocellular storage, breakdown, and catabolism of LDs is essential to effectively prevent, reduce, and treat MASLD and is the focus of this proposal. Significant evidence, based on our work and others, implicates the selective targeting and breakdown of hepatic LDs by the autophagic machinery during a process called lipophagy. We recently identified a novel autophagic process termed “microlipophagy” (MiLi) by which lysosomes fuse, engulf, and degrade LDs directly. Our evidence indicates that MiLi is the predominant mechanism by which the hepatocyte catabolizes LDs. We also found that macropinocytosis (MP; “large cellular drinking”) plays a significant role in regulating hepatocellular lipid stores by forming large macropinosomes from the plasmalemma that traffic into the cell to mediate LD-lysosome fusion. We have demonstrated that important components of these essential cellular processes are large and small GTPases. These include the Ras-like Rab GTPases that control nearly all membrane-trafficking processes in the hepatocyte while the dynamin (Dyn2) family of large GTPase mechanoenzymes mediate membrane scission/fusion throughout the cell. Further, we have compelling evidence that this MiLi process occurs at the ER surface to catabolize nascent LDs as they form. Equally exciting to us is our finding that Mayo patients with MASLD possess mutant variants of these proteins that cause hepatocellular steatosis in culture. From these observations, the central hypothesis of this proposal predicts that together the MP and MiLi processes play a central role in hepatocellular lipid catabolism and are both supported and regulated by the synergistic actions of specific Rabs (Rab8a/10) and Dyn2 GTPases, which are altered and disrupted during steatosis. The strategy of this proposal utilizes state of the art hepatocellular imaging approaches, coupled with electron microscopy, molecular methods, and membrane biochemistry. This is correlated with data gleaned from patients, and 4 distinct and novel conditional knock out mouse models we have designed. Aim 1 will define the physiological contributions of MP to hepatocellular lipid stores and steatosis by testing how MP drives MiLi via a novel protein complex of Rab 8a/10, the large GTPase Dyn2, and a new endocytic adapter (SH3D19) we have identified. Aim 2 will define the mechanisms of a novel process we have observed that is focused on lysosomal targeting and catabolism of nascent LDs at the ER as they form that utilizes the actin cytoskeleton and ER-phagy/autophagy receptors. Completion of these studies will provide valuable insights into hepatocellular lipid metabolism, the underlying basis for hepatic steatosis, and potential novel strategies for therapeutic intervention in MASLD.

Department of Labor

AWARD PURPOSE THE PURPOSE OF BOOST GO IS TO PREPARE YOUNG ADULTS FOR EMPLOYMENT THROUGH EDUCATION AND TRAINING, PAID WORK EXPERIENCES, MENTORSHIP, AND LEADERSHIP DEVELOPMENT WITH DELIVERY OF EVIDENCE-BASED PRACTICES INTERVENTIONS. ACTIVITIES PERFORMED BOOST GO WILL SUPPORT JUSTICE INVOLVED YOUNG ADULTS FOR EMPLOYMENT AND VIOLENCE PREVENTION BY 1. HELPING YOUNG ADULTS TO INCREASE THEIR CONFLICT RESOLUTION SKILLS AND DEVELOP STRATEGIES TO PREVENT AND AVOID VIOLENCE. THIS WILL BE ACHIEVED IN PARTNERSHIP WITH SKY RANCH BEHAVIORAL SERVICES TO PROVIDE VIOLENCE PREVENTION, MENTORING, AND LEADERSHIP DEVELOPMENT THROUGH DELIVERY OF EVIDENCE-BASED INTERVENTIONS OF AGGRESSION REPLACEMENT TRAINING® ART) AND MENTORS IN VIOLENCE PREVENTION (MVP) CURRICULUM DESIGNED BY UNIVERSITY OF NORTHERN IOWA CENTER FOR VIOLENCE PREVENTION (CVP). PARTNERS WILL COLLABORATE TO RECRUIT AND TRAIN MULTICULTURAL MENTORS WITH LIVED EXPERIENCE. 2. PREPARING YOUNG ADULTS FOR THE WORLD OF WORK BY HELPING YOUNG ADULTS IDENTIFY CAREER INTERESTS, ATTAIN RELEVANT SKILLS, AND GAIN WORK EXPERIENCE. BOOST GO WILL ENSURE PARTICIPANTS RECEIVE COMPREHENSIVE EMPLOYMENT AND CAREER SERVICES UTILIZING STEP ON UP® CAREER READINESS AND GROWTH FOCUSED CASE MANAGEMENT (GFCM), RESULTING IN A CUSTOMIZED INDIVIDUAL DEVELOPMENT PLAN (IDP). PARTICIPANTS WILL GAIN WORK EXPERIENCE IN EMPLOYMENT, APPRENTICESHIP, INTERNSHIP; AND/OR ON-THE-JOB TRAINING WITH HIGH PRIORITY EMPLOYER PARTNERS HIGH DEMAND CAREERS, BASED ON CURRENT LABOR MARKET INFORMATION (LMI) AND IOWA WORKFORCE DEVELOPMENT TO INCLUDE CHILDCARE, CONSTRUCTION, FOOD/MEAT PROCESSING, HEALTH CARE, MAINTENANCE/ SAFETY, COMMERCIAL TRUCKING, WAREHOUSE LOGISTICS/OPERATIONS, AND WELDING. WRAPAROUND SERVICES TO ADDRESS HOUSING, MENTAL HEALTH, ADDICTION, CHILDCARE, LEGAL SERVICES, WILL BE CUSTOMIZED TO EACH INDIVIDUAL. DELIVERABLES OUTCOMES WILL EXCEED ALL REQUIRED PERFORMANCE OUTCOMES TO INCLUDE A 73% EMPLOYMENT RATE- SECOND QUARTER AFTER EXIT, 65% EMPLOYMENT RATE- FOURTH QUARTER AFTER EXIT, 6,000 MEDIAN EARNINGS, 60% CREDENTIAL ATTAINMENT, 73% MEASURABLE SKILL GAIN, LESS THAN 3% ARRESTS FOR VIOLENT CRIMES, AND LESS THAN AN 8% RECIDIVISM RATE. INTENDED BENEFICIARY BOOST GO WILL REACH AND SERVE 180 YOUNG ADULTS 18-24 YEARS OLD MOST IMPACTED BY POVERTY AND CRIME, WITH PRIORITY ON REACHING MINORITY COMMUNITIES IN THE CENSUS TRACTS. SUBRECIPIENT ACTIVITIES N/A

Artspace Committee

The Artspace Committee will host a free public event featuring games, food, art, and karaoke based on a 1980's cultural theme. It will be held at Artspace Hiawatha Lofts located at 843 Hiawatha Pl S. The event will take place on May 26, 2018 from 5 pm - 10 pm.

Ballard Public Art Committee

The Ballard Alliance, Ballard Public Art Committee, and Parks and Rec (the parties) aim to increase community ownership of Ballard Commons Park, the only open green space in the core of downtown Ballard. For years, the parties have collaborated on free park activities and have developed plans for a children's play area in the park which will break ground this year. For this grant proposal, the parties aim to conduct a community painted mural on a utility building in the NW corner of the park with a local artist during the Seattle One Day of Service. This project was originally proposed in 2020 but did not receive funding due to the pandemic. For this project, the artist will paint the outline of the mural on the utility building prior to the One Day of Service so that during the event, volunteers will fill in the mural in a paint by numbers approach. The mural, with existing park activities and future children's play area, will benefit the park and the community it serves.

Ballard Public Art Committee

The Ballard Public Art Committee will incorporate more public art on the streets of Ballard through the Utility Box Beautification Project. Located between 17th Avenue NW and 24th Avenue NW, there are six Seattle Department of Transportation utility boxes on NW Market Street that the committee will cover with vinyl wrap art. This project will be completed by August 31, 2019.

Ballard Public Art Committee

The Ballard Public Art Committee will incorporate more public art on the streets of Ballard through a second utility box beautification project. Located on Market Street and 57th Ave NW there are three utility boxes the committee will cover with vinyl wrap art. This project will be completed by July 31, 2020.

Barr Foundation

Supports arts and culture in Boston and New England, with focus on creative economy, arts education, and cultural equity.